Smith+Nephew cuts guidance on weak orthopaedics demand

Smith+Nephew reported Q3 revenue of $1.55 billion, up 3.4% year over year, but cut full-year revenue growth guidance to around 3% from 4% and trading profit growth guidance to around 4% from 8%; expected trading profit fell to approximately $1.25 billion from $1.3 billion. Free cash flow guidance was reduced to around $750 million from $800 million, while the 95% cash-conversion target remained unchanged. Talks with Johnson & Johnson about a possible combination of Orthopaedics with DePuy Synthes have ended, and the company said it will continue considering strategic options; its $500 million buyback remains on track, with $250 million completed by Q3 end.

Analysis

The key read-through is not just slower U.S. orthopaedics: the larger cut to trading-profit growth than revenue growth points to operating leverage working against Smith+Nephew, while lower free-cash-flow guidance reduces near-term capacity for buybacks or other strategic uses. The company’s expectation that U.S. weakness persists into Q4 makes the next guidance update more important than the reported quarter. Sports Medicine and Wound Management strength may cushion, but does not yet demonstrate that growth can offset orthopaedics’ drag.

The failed DePuy Synthes discussions remove a near-term transaction catalyst for Smith+Nephew; continued strategic review is optionality, not a valuation floor. For Johnson & Johnson, the end of talks is not itself a material fundamental signal absent evidence of changed DePuy strategy or economics. Competitors such as Stryker and Zimmer Biomet could benefit if Smith+Nephew’s execution problems translate into surgeon or hospital share shifts, but that is a hypothesis to test against procedure and share data—not an automatic read-through from one company’s results.

Near term, expect scrutiny of guidance credibility and cash conversion. Over 1–3 months, watch U.S. hip/knee procedure volumes, Smith+Nephew’s Q4 trading and any strategic-review update. Over 6–18 months, sustained share losses or a sale/separation could reshape the orthopaedics outlook. Contrarian risk: the cuts may already be reflected in the share price, while strong non-orthopaedics franchises and strategic optionality could limit downside. Without valuation and price-action context, favor a hedged relative-value expression over an outright short.

Key Decisions for Investors

• Consider a modest short in Smith+Nephew against a long broad medtech basket, sized as a relative-value position rather than a high-conviction standalone short. Reassess after the next U.S. orthopaedics update; the thesis weakens if Q4 execution stabilizes and profit growth tracks or exceeds revenue growth.
• Do not trade Johnson & Johnson on the collapsed talks alone. Treat any renewed DePuy-related transaction report as a catalyst to verify, not as evidence of a change in J&J earnings or valuation.
• Track U.S. hip and knee procedure trends, Smith+Nephew’s segment growth and operating-profit progression, free-cash-flow delivery versus guidance, and any strategic-review announcement. Persistent weakness or another guidance reduction would strengthen the relative short; improving growth and cash delivery would falsify it.
• Before sizing an outright position, verify current valuation, recent share-price reaction, consensus revisions, and Smith+Nephew’s balance-sheet and buyback funding details. The article does not establish whether the guidance reset is already priced in or whether the buyback constrains financial flexibility.